Tailoring of hormonal therapy in prostate cancer

Newling, Don

doi:10.1038/sj.pcan.4500400

Cited by 8 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study set-up was motivated by the common practice of using AD in the treatment of early-stage PC outside clinical trials. We chose to test 12 months of treatment in view of superior effects shown compared to shorter (Gleave et al, 2001), and avoided longer treatment in order to delay the development of hormone-resistant disease (Newling, 2000).…”

Section: Discussionmentioning

confidence: 99%

Androgen deprivation and cognition in prostate cancer

et al. 2003

View full text Add to dashboard Cite

Androgen deprivation (AD) is commonly used in neoadjuvant and adjuvant setting with prostate cancer (PC) radiotherapy. This prospective study assessed whether cognitive functioning is impaired during 12 months of AD therapy. Longitudinal testing of 25 patients treated with AD and curative radiotherapy was undertaken at baseline, and at 6 and 12 months. CogniSpeed r software was used for measuring attentional performances. Other cognitive performances were evaluated using verbal, visuomotor and memory tests. The Beck depression inventory was employed to evaluate depressive mood and EORTC QLQ-C30 for quality of life (QoL). During longitudinal testing of the AD group, no impairment in cognitive performances was found. Instead, improvement was observed in object recall (immediate, P ¼ 0.035; delayed, Po0.001), and in semantic memory (P ¼ 0.037). In QoL, impairment in physical function was observed. Androgen deprivation of 12 months appears to be associated with preserved cognitive functioning, although physical impairment occurs. These results have implications for counseling and psychosocial support of patients in the context of treatment options in PC.

show abstract

Section: Discussionmentioning

confidence: 99%

Androgen deprivation and cognition in prostate cancer

et al. 2003

View full text Add to dashboard Cite

show abstract

“…The effects of the ET regimen were highly efficacious for localized and locally advanced PC and the benefit provided by prostatectomy may not be recognized readily in men receiving endocrine therapy [37,38]. However, ET should be administered selectively as the therapy presents with various side-effects like hot flushes, male sexual dysfunction and osteoporosis [39][40][41]. Additionally, it has been reported that the usage of ET has significantly impaired the quality of life including physical functioning, fatigue and psychological distress in asymptomatic patients suffering from non-metastatic PC [42].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of overall survival rate of different therapies in the treatment of T1–T3 prostate cancer: a network meta-analysis

Chen¹,

Du²,

Shao³

et al. 2018

neo

View full text Add to dashboard Cite

We performed this network meta-analysis (NMA) in order to compare the overall survival rate of six different therapies of T1-T3 prostate cancer (PC). The therapies include radiotherapy (RT), endocrine therapy (ET), Cryoablation (CRYO), radical prostatectomy (RP), RT+ET and RP+ET. Pubmed, Embase, Cochrane Library, Google Scholar, Web of Science and MEDLINE were searched to collect relevant literature from the inception of the study till February 2017. Cohort studies meeting the inclusion criteria were included in the study. A combination of direct and indirect evidence was performed to evaluate the odds ratio (OR) and draw surface under the cumulative ranking curves (SUCRA). Nine eligible cohort studies were included in this NMA, including 20,644 patients suffering from T1-T3 PC. The pairwise meta-analysis revealed that compared with the ET regimen, the RP and RP+ET regimens exhibited comparatively higher overall survival rates (OR = 2.81, 95%CI = 2.09 ~ 3.78; OR = 3.15，95%CI = 1.80 ~ 5.50, respectively). The results of SUCRA values demonstrated that the RP + ET regimen occupied the first place (89.5%) in terms of overall survival rate, and the RP regimen came second (84.83%). Thus, the RP+ET regimen had better efficacy in the treatment of T1-T3 PC in combined-therapeutic regimens, and the RP regimen presented better efficacy in mono-therapeutic regimen. Our findings indicate that the RP+ET regimen had better efficacy on improving the overall survival rate of T1-T3 PC patients, and the RP regimen ranked second.

show abstract

“…In addition, endocrine therapy should be indicated selectively 21 because the therapy is not harmless and is associated with adverse events including hot flush, male sexual dysfunction or osteoporosis 22,23 . It has also been reported that endocrine therapy has significantly impaired the quality of life including physical function, fatigue and psychological distress in asymptomatic patients with non‐metastatic prostate cancer 24 .…”

Section: Discussionmentioning

confidence: 99%

Endocrine therapy with or without radical prostatectomy for T1b‐T3N0M0 prostate cancer

et al. 2004

View full text Add to dashboard Cite

Background : We retrospectively compared the 5-year survival rates of T1b-T3N0M0 prostate cancer patients treated either by endocrine therapy plus radical prostatectomy or endocrine therapy alone. Methods : Clinical T1b-T3N0M0 prostate cancer patients were enrolled at 104 institutions in Japan. They were assigned to study 1 ( n = 176), if they were indicated to prostatectomy, if not indicated, they were assigned to study 2 ( n = 151). The indication of prostatectomy was based on the clinical judgement of physicians and/or patients. Those assigned to study 1 underwent prostatectomy and adjuvant endocrine therapy with or without preoperative androgen deprivation. Those assigned to study 2 were treated with leuprorelin acetate with or without chlormadinone acetate. They were followed-up every 3 months until death or for 5 years and over.Results : Those assigned to study 1 were younger (mean age 67.2 vs 75.7 years), less advanced in clinical stage, and had lower prostate specific antigen levels (mean 43.8 vs 103.6 ng/mL). Death for any reason was observed less frequently in study 1 ( n = 29, 16%) than study 2 ( n = 50, 33%), and the 5-year overall survival rate was higher in study 1 (87 vs. 68%). However, prostate cancer deaths were comparatively seldom (9% in study 1 and 7% in study 2), resulting in the identical 5-year cause specific survival rate in both study groups (91%). In both study groups the overall survival was almost equal to the natural survival of age-matched men. Conclusions : Endocrine therapy offers a reasonable survival rate in T1b-T3 prostate cancer patients within a 5-year follow-up. Observation will be extended to determine 10-year outcomes.

show abstract

Tailoring of hormonal therapy in prostate cancer

Cited by 8 publications

References 14 publications

Androgen deprivation and cognition in prostate cancer

Androgen deprivation and cognition in prostate cancer

Evaluation of overall survival rate of different therapies in the treatment of T1–T3 prostate cancer: a network meta-analysis

Endocrine therapy with or without radical prostatectomy for T1b‐T3N0M0 prostate cancer

Contact Info

Product

Resources

About